Harvest Fund Management Co. Ltd Trims Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Harvest Fund Management Co. Ltd cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 96.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 675 shares of the company’s stock after selling 20,128 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Novo Nordisk A/S were worth $80,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Advisor OS LLC increased its stake in Novo Nordisk A/S by 0.6% in the second quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock valued at $1,994,000 after purchasing an additional 82 shares during the period. Cascade Financial Partners LLC increased its position in Novo Nordisk A/S by 2.3% in the 2nd quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock valued at $543,000 after acquiring an additional 84 shares during the period. Novare Capital Management LLC raised its stake in Novo Nordisk A/S by 3.2% during the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after acquiring an additional 85 shares during the last quarter. AA Financial Advisors LLC lifted its position in Novo Nordisk A/S by 3.2% during the 2nd quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after acquiring an additional 86 shares during the period. Finally, Steel Grove Capital Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2.3% in the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after purchasing an additional 86 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on NVO shares. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $106.12 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company has a market cap of $476.22 billion, a P/E ratio of 34.34, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42. The business has a fifty day moving average of $113.80 and a two-hundred day moving average of $128.33.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.